T1	CHEM 74 83	rituximab
#1	AnnotatorNotes T1	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	CHEM 91 102	azatioprina
#2	AnnotatorNotes T2	C0004482; azathioprine; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T3	PROC 651 687	Consentimiento informado por escrito
#3	AnnotatorNotes T3	C0811741; Obtain informed written consent; Health Care Activity
T4	DISO 144 159	vasculitis ANCA
#4	AnnotatorNotes T4	C2717865; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Disease or Syndrome
T5	CHEM 155 159	ANCA
#5	AnnotatorNotes T5	C0103647; Antineutrophil Cytoplasmic Antibodies; Immunologic Factor
T6	PROC 182 238	Estudio internacional, abierto, aleatorizado, controlado
T7	CHEM 251 260	rituximab
#6	AnnotatorNotes T7	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	CHEM 338 380	anticuerpos anti-citoplasma del neutrófilo
T9	CHEM 382 386	ANCA
#7	AnnotatorNotes T9	C0103647; Antineutrophil Cytoplasmic Antibodies; Immunologic Factor
T10	DISO 413 434	Enfermedad autoinmune
#8	AnnotatorNotes T10	C0004364; Autoimmune Diseases; Disease or Syndrome
T11	ANAT 449 465	vasos sanguíneos
#9	AnnotatorNotes T11	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C1283786; Entire blood vessel; Body Part, Organ, or Organ Component
T12	PROC 56 70	Ensayo clínico
#10	AnnotatorNotes T12	C0008976; Clinical Trials; Research Activity
T13	DISO 569 578	infección
#11	AnnotatorNotes T13	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T14	DISO 606 621	Vasculitis ANCA
#12	AnnotatorNotes T14	C2717865; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Disease or Syndrome
T15	CHEM 617 621	ANCA
#13	AnnotatorNotes T15	C0103647; Antineutrophil Cytoplasmic Antibodies; Immunologic Factor
T16	PROC 751 762	Diagnóstico
#14	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	DISO 766 792	vasculitis asociada a ANCA
#15	AnnotatorNotes T17	C2717865; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Disease or Syndrome
T18	DISO 794 820	poliangiitis granulomatosa
#16	AnnotatorNotes T18	C3495801; Granulomatosis with polyangiitis; Disease or Syndrome
T19	DISO 822 829	Wegener
#17	AnnotatorNotes T19	C3495801; Granulomatosis with polyangiitis; Disease or Syndrome
T20	DISO 833 858	poliangiitis microscópica
#18	AnnotatorNotes T20	C2347126; Microscopic Polyarteritis; Disease or Syndrome
T21	PROC 932 936	ANCA
#19	AnnotatorNotes T21	C0201530; Antineutrophil cytoplasmic antibody measurement; Laboratory Procedure
T22	PROC 968 973	ELISA
#20	AnnotatorNotes T22	C0014441; Enzyme-Linked Immunosorbent Assay; Laboratory Procedure
T23	PROC 980 999	inmunofluorescencia
#21	AnnotatorNotes T23	C0079603; Immunofluorescence assay; Laboratory Procedure
T24	CHEM 265 276	azatioprina
#22	AnnotatorNotes T24	C0004482; azathioprine; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T25	DISO 1143 1168	granulomatosis de Wegener
#23	AnnotatorNotes T25	C3495801; Granulomatosis with polyangiitis; Disease or Syndrome
T26	PROC 1243 1263	terapia de inducción
#24	AnnotatorNotes T26	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T27	PROC 1373 1384	Tratamiento
#25	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	CHEM 1396 1414	agentes biológicos
#26	AnnotatorNotes T28	C0005515; Biological Factors; Biologically Active Substance
T29	ANAT 1431 1443	linfocitos B
#27	AnnotatorNotes T29	C0004561; B-Lymphocytes; Cell
T30	CHEM 1450 1459	rituximab
#28	AnnotatorNotes T30	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	CHEM 1462 1471	belimumab
#29	AnnotatorNotes T31	C1723401; belimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	DISO 315 380	vasculitis asociadas a anticuerpos anti-citoplasma del neutrófilo
T33	CHEM 788 792	ANCA
#30	AnnotatorNotes T33	C0103647; Antineutrophil Cytoplasmic Antibodies; Immunologic Factor
T34	Date 13 17	2012
T35	LIVB 689 699	individuos
#31	AnnotatorNotes T35	C0027361; Persons; Population Group
T36	Age 708 738	igual o superior a los 15 años
T37	Date 947 953	actual
T38	LIVB 1182 1191	pacientes
#32	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	Age 1301 1310	< 15 años
T40	Age 1312 1320	<18 años
T41	Neg_cue 1336 1338	no
T42	LIVB 1347 1368	pacientes pediátricos
#33	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group + C0008059; Child; Age Group
T43	Duration 1476 1495	los 6 meses previos
T44	ANAT 370 380	neutrófilo
#34	AnnotatorNotes T44	C0027950; neutrophil; Cell
T45	PHYS 525 532	defensa
#35	AnnotatorNotes T45	C1817756; Immune System Processes; Organ or Tissue Function (?)
T46	DISO 1021 1032	recurrencia
#36	AnnotatorNotes T46	C2825055; Recurrence (disease attribute); Pathologic Function
T47	PROC 1088 1092	BVAS
#37	AnnotatorNotes T47	C5395416; Assessment using Birmingham Vasculitis Activity Score; Health Care Activity
T48	PROC 1094 1130	Birmingham Vasculitis Activity Score
#38	AnnotatorNotes T48	C5395416; Assessment using Birmingham Vasculitis Activity Score; Health Care Activity
T49	PROC 1170 1174	BVAS
#39	AnnotatorNotes T49	C5395416; Assessment using Birmingham Vasculitis Activity Score; Health Care Activity
A1	Population_data T42 Age
A3	Status T27 History_of
A2	Status T28 History_of
A4	Status T30 History_of
A5	Status T31 History_of
#40	AnnotatorNotes T8	C0103647; Antineutrophil Cytoplasmic Antibodies; Immunologic Factor
#41	AnnotatorNotes T32	C2717865; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Disease or Syndrome
#42	AnnotatorNotes T37	C0521116; Current (present time); Temporal Concept 
T50	Observation 129 137	remisión
#43	AnnotatorNotes T50	C0544452; Disease remission; Finding
R1	Before Arg1:T4 Arg2:T50	
R2	Causes Arg1:T5 Arg2:T4	
T51	Observation 303 311	remisión
#44	AnnotatorNotes T51	C0544452; Disease remission; Finding
R3	Causes Arg1:T8 Arg2:T32	
R4	Causes Arg1:T9 Arg2:T32	
R5	Before Arg1:T32 Arg2:T51	
R6	Overlap Arg1:T2 Arg2:T50	
R7	Overlap Arg1:T1 Arg2:T50	
R8	Overlap Arg1:T24 Arg2:T51	
R9	Overlap Arg1:T7 Arg2:T51	
R10	Location_of Arg1:T11 Arg2:T10	
R11	Causes Arg1:T15 Arg2:T14	
R12	Has_Age Arg1:T35 Arg2:T36	
R13	Causes Arg1:T33 Arg2:T17	
R14	Overlap Arg1:T21 Arg2:T37	
A6	Status T21 History_of
T52	Result_or_Value 937 945	positivo
#45	AnnotatorNotes T52	C1446409; Positive; Finding
R15	Has_Result_or_Value Arg1:T21 Arg2:T52	
R18	Overlap Arg1:T22 Arg2:T37	
R19	Overlap Arg1:T23 Arg2:T37	
A7	Status T22 History_of
A8	Status T23 History_of
T53	Result_or_Value 1046 1058	1 item mayor
R20	Has_Result_or_Value Arg1:T46 Arg2:T53	
T54	Result_or_Value 1061 1070	3 menores
R21	Has_Result_or_Value Arg1:T46 Arg2:T54	
R22	Experiences Arg1:T38 Arg2:T46	
R23	Experiences Arg1:T38 Arg2:T25	
R24	Experiences Arg1:T38 Arg2:T47	
R25	Experiences Arg1:T38 Arg2:T48	
R26	Experiences Arg1:T38 Arg2:T49	
T55	Observation 1225 1233	remisión
#46	AnnotatorNotes T55	C0544452; Disease remission; Finding
R27	After Arg1:T55 Arg2:T26	
R28	Experiences Arg1:T38 Arg2:T55	
R29	Before Arg1:T25 Arg2:T55	
R30	Before Arg1:T55 Arg2:T46	
R31	Negation Arg1:T41 Arg2:T42	
R32	Has_Age Arg1:T42 Arg2:T40	
R33	Used_for Arg1:T28 Arg2:T27	
R34	Used_for Arg1:T30 Arg2:T27	
R35	Used_for Arg1:T31 Arg2:T27	
R36	Overlap Arg1:T31 Arg2:T43	
R37	Overlap Arg1:T30 Arg2:T43	
R38	Overlap Arg1:T28 Arg2:T43	
R16	Experiences Arg1:T38 Arg2:T26	
T56	Quantifier_or_Qualifier 1415 1443	dirigidos hacia linfocitos B
R17	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T56	
A9	Experiencer T35 Patient
A10	Experiencer T38 Patient
A11	Experiencer T42 Patient
